EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Amoxicillin-non-susceptible Streptococcus pneumoniae causing invasive pneumonia: serotypes, clones, and clinical impact

Jordi Càmara iD, Inmaculada Grau, Aida González-Díaz, Naiara Santos, Fe Tubau-Quintano, Sara Martí, Judith Peñafiel, María Ángeles Domínguez, Josefina Liñares, Román Pallarés, Carmen Ardanuy iD

Antimicrobial Agents and Chemotherapy · 06.08.2025 · 69 (8)

DOI: 10.1128/aac.00237-25 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.08.2025. Verfasst von Jordi Càmara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Spain. Hauptthemen laut MEDLINE: Amoxicillin, Streptococcus pneumoniae, Anti-Bacterial Agents, Pneumonia, Pneumococcal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amoxicillin is one of the most commonly used antibiotics to treat pneumococcal infections. We analyzed the epidemiology and clinical impact of amoxicillin non-susceptibility in invasive pneumococcal pneumonia. This is an observational study based on prospectively collected data at Bellvitge University Hospital (Barcelona, Spain) from 1994 to 2020. Isolates were tested for antibiotic susceptibility, serotyped, and genotyped. Clinical characteristics and 30 day mortality were evaluated using independent Cox proportional hazards models. We analyzed 1,663 episodes. While the proportion of isolates susceptible to amoxicillin increased from 72.9% (1994–2001) to 91.4% (2016–2020), the proportion of isolates with MIC > 2 mg/L remained stable (4.8% and 5.3%, respectively). A single lineage (GPSC6; serotypes 9V, 14, and 11A) accounted for 56.5% of non-susceptible strains. High McCabe scores (ultimately fatal: HR 2.87 [2.10–3.92] and rapidly fatal: HR 4.98 [3.50–7.09]), along with parameters linked to disease severity such as leukopenia (HR 2.14 [1.63–2.82]), shock (HR 3.47 [2.63–4.57]), respiratory failure (HR 4.26 [2.63–6.89]), and bilobar pneumonia (HR 1.44 [1.09–1.90]), were associated with 30 day mortality. The risk of mortality was higher in episodes treated with amoxicillin than with third-generation cephalosporins (HR 1.81 [1.28–2.56]), especially in episodes with amoxicillin MIC > 2 mg/L (HR 6.14 [1.65–22.80]). Amoxicillin therapy was not associated with increased mortality in patients with a non-fatal McCabe score (HR 1.49 [0.62–3.55]), but it was in the ultimately fatal/rapidly fatal group (HR 1.97 [1.34–2.90]). In addition to the crucial importance of host factors in the outcome of invasive pneumococcal pneumonia, our data indicate that amoxicillin yields poorer outcomes compared to third-generation cephalosporins, particularly in patients with a worse prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmoxicillinStreptococcus pneumoniaeAnti-Bacterial AgentsPneumonia, PneumococcalHumansMicrobial Sensitivity TestsMaleFemaleMiddle AgedAgedSerogroupSpainProspective StudiesAdultAged, 80 and over

Stichwörter der Autor:innen

Streptococcus pneumoniaeamoxicillininvasive pneumococcal diseasemortalitypneumonia

Substanzen

AmoxicillinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Clinical Microbiology, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Spain.
  • Research Network for Respiratory Diseases (CIBERES-CB06/06/0037), ISCIII, Madrid, Spain.
  • Infectious Diseases Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Spain.
  • Biostatistics Unit, Bellvitge Biomedical Research Institute-IDIBELL, L'Hospitalet de Llobregat, Spain.
  • Department of Medicine, University of Barcelona, Barcelona, Spain.
  • Department of Pathology and Experimental Therapeutics, University of Barcelona, Barcelona, Spain.

ORCID-Profile: Jordi Càmara, Carmen Ardanuy

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Càmara, J., Grau, I., González-Díaz, A., Santos, N., Tubau-Quintano, F., Martí, S., Peñafiel, J., Ángeles Domínguez, M., Liñares, J., Pallarés, R., & Ardanuy, C. (2025). Amoxicillin-non-susceptible Streptococcus pneumoniae causing invasive pneumonia: serotypes, clones, and clinical impact. Antimicrobial Agents and Chemotherapy, 69(8). https://doi.org/10.1128/aac.00237-25

Vancouver

Càmara J, Grau I, González-Díaz A, Santos N, Tubau-Quintano F, Martí S, et al. Amoxicillin-non-susceptible Streptococcus pneumoniae causing invasive pneumonia: serotypes, clones, and clinical impact. Antimicrobial Agents and Chemotherapy. 2025;69(8). doi:10.1128/aac.00237-25

BibTeX
@article{Cmara2025,
  author = {Càmara, Jordi and Grau, Inmaculada and González-Díaz, Aida and Santos, Naiara and Tubau-Quintano, Fe and Martí, Sara and Peñafiel, Judith and Ángeles Domínguez, María and Liñares, Josefina and Pallarés, Román and Ardanuy, Carmen},
  title = {Amoxicillin-non-susceptible Streptococcus pneumoniae causing invasive pneumonia: serotypes, clones, and clinical impact},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {8},
  doi = {10.1128/aac.00237-25}
}
Kostenlos starten →